However, because of the potential side effects associated with the Fc region of full-length antibodies and the limited tumor penetration of large IgG molecules, researchers have extended immunocytokine development to include smaller antibody fragments, such as scFv formats linked to WT IL-2 and directed against various tumor-associated antigens (TAAs) (9). This evidence concerns the gene IL2 and neoplasm.